PepVault News · Calendar
What’s coming for peptides.
FDA decisions, trial results, the big meetings and the results calls on the peptides and GLP-1s the crowd follows. Each date is the one its primary source gives, linked.
Newsletter · Weekly
The weekly peptide briefing.
Get the week’s peptide news and what’s coming, every Monday.
October 2026
-
Results call
Eli Lilly's Q3 2026 results and earnings call
Eli Lilly reports its third-quarter 2026 results and holds its earnings call on Oct 29, 2026, at 10:00 AM EDT.
Why it matters: Sales of Mounjaro, Zepbound and Foundayo, plus pipeline news; Lilly's Q2 release carried the retatrutide filing plan.
November 2026
-
Results call
Novo Nordisk's nine-month 2026 results
Novo Nordisk publishes its financial results for the first nine months of 2026 on Nov 4, 2026.
Why it matters: Wegovy, Ozempic and Wegovy pill sales, and any update on CagriSema's US review, which Novo expects to end in Q4 2026.
Source: Novo Nordisk H1 2026 financial report (Form 6-K), Financial Calendar
-
Conference
The Liver Meeting 2026 (AASLD, Denver)
The American Association for the Study of Liver Diseases holds The Liver Meeting at the Colorado Convention Center in Denver from Thursday, Nov 5 to Monday, Nov 9, 2026.
Why it matters: The main US liver meeting; MASH (fatty liver) results for GLP-1 and glucagon drugs often appear here.
-
Conference
ObesityWeek 2026 (The Obesity Society, Washington, DC area)
ObesityWeek, The Obesity Society's annual meeting, runs Nov 14–17, 2026, at the Gaylord National Resort & Convention Center in National Harbor, Maryland, outside Washington, DC.
Why it matters: The main US obesity meeting; new data on GLP-1 and next-generation obesity drugs is often presented here.
-
Regulation
FDA's final rule adding substances to the 503A Bulks List (2019 proposal)
FDA plans to finalize its 2019 proposal (84 FR 46688) to add more bulk drug substances to the 503A Bulks List and to name others it won't include. November 2026 is FDA's planned month in its regulatory agenda.
Why it matters: It settles which ingredients from the 2019 proposal US pharmacies may compound; FDA says newer nominations will come in later rules.
FDA's planned month (Final Rule 11/00/2026); agenda dates often slip.
-
Regulation
FDA's proposed rule on shipping compounded drugs across state lines (503A MOU)
FDA plans a proposed rule on 503A compounded drugs shipped out of state: a standard memorandum of understanding (MOU) for State Boards of Pharmacy, and the 5% out-of-state limit in states that don't sign it. November 2026 is FDA's planned month.
Why it matters: It sets how much a compounding pharmacy may ship to other states, which matters for compounded GLP-1s and peptides sold online.
FDA's planned month (NPRM 11/00/2026); agenda dates often slip.
-
Trial results
Retatrutide vs tirzepatide head-to-head (TRIUMPH-5)
Lilly's phase 3 TRIUMPH-5 compares retatrutide with tirzepatide for weight loss in adults with obesity. The trial's registered finish date for its main goal is November 2026; Lilly hasn't announced when results come.
Why it matters: A direct phase 3 comparison of retatrutide with tirzepatide (Zepbound, Mounjaro) on weight loss.
Registry only: primary completion 2026-11 (estimated); record last updated 2026-07-20.
Source: ClinicalTrials.gov NCT06662383 (sponsor Eli Lilly and Company)
December 2026
-
Results call
Lilly Innovation Day 2026 (investor R&D event)
Eli Lilly holds Lilly Innovation Day 2026 on Dec 7, 2026, from 9:00 AM to 1:00 PM EST, an investor event listed on its investor site. It is not a results call, and Lilly has not posted an agenda.
Why it matters: An investor event from the maker of Zepbound, Foundayo and retatrutide; Lilly has not said what it will cover.
Kind 'earnings' is the nearest fit for an investor event.
Q4 2026
The source gives the quarter, not the day.
-
Q4 2026
Trial results
Aleniglipron (Structure's GLP-1 pill): body-composition, diabetes and switch data
Structure Therapeutics says data from three aleniglipron trials are on track for Q4 2026: body composition over 44 weeks, people with type 2 diabetes and obesity, and SWITCH, moving from an approved GLP-1 injection to the daily pill.
Why it matters: SWITCH tests whether people keep their weight off after moving from a GLP-1 injection to a once-daily pill.
Source: Structure Therapeutics Q2 2026 results (Form 8-K, exhibit 99.1)
-
Q4 2026
Trial results
CagriSema at lower doses (REDEFINE 9): full results
Novo Nordisk completed REDEFINE 9, a 68-week trial of CagriSema 1.0/1.0 mg and 1.7/1.7 mg; both gave more weight loss than placebo. Novo says the detailed results will be presented at a scientific conference later in 2026.
Why it matters: The first detailed look at CagriSema below its full 2.4/2.4 mg dose.
'Later in 2026' placed in Q4 2026; Novo names no conference.
Source: Novo Nordisk H1 2026 financial report (Form 6-K, Aug 4, 2026)
-
Q4 2026
FDA decision
FDA decision on CagriSema for weight management
Novo Nordisk expects the FDA's decision on CagriSema, a weekly injection combining the amylin analog cagrilintide with semaglutide, for weight management in the fourth quarter of 2026. Novo has not published an exact decision date.
Why it matters: If approved, US patients get amylin (cagrilintide) and semaglutide together in one weekly weight-loss shot.
Also listed as a Q4 2026 'US decision' in Novo's H1 2026 report milestone table.
Source: Novo Nordisk Capital Markets Day 2026, obesity presentation (Sep 21, 2026)
-
Q4 2026
FDA decision
FDA decision on the 25 mg Ozempic pill for type 2 diabetes
Novo Nordisk submitted a 25 mg dose of the Ozempic pill (oral semaglutide) for type 2 diabetes to the FDA earlier in 2026 and expects the decision during Q4 2026.
Why it matters: A higher oral semaglutide dose for type 2 diabetes; the same 25 mg strength is already sold for weight as the Wegovy pill.
Source: Novo Nordisk H1 2026 financial report (Form 6-K, Aug 4, 2026)
-
Q4 2026
Regulation
FDA's interim access policy for compounding certain peptides (at White House review)
FDA's 'Interim Access Policy for Compounding Using Certain Peptides' (RIN 0910-ZD94, a notice) has been under White House OIRA review since Oct 14, 2026. Its text and the peptides it covers are not public yet, and no publication date is stated.
Why it matters: By its title, it sets FDA's interim stance on compounding with certain peptides, which shapes what US pharmacies may make.
Placed in Q4 2026 by convention; OIRA states no end date. Our Oct 15 story on the OIRA listing: fda-interim-access-policy-compounding-peptides.
Source: reginfo.gov (OIRA), pending EO 12866 review, RIN 0910-ZD94
-
Q4 2026
Regulation
FDA's next 503A Bulks List proposal (which ingredients pharmacies may compound)
FDA plans a proposed rule naming more bulk drug substances it proposes to add to, or keep off, the 503A Bulks List. Its regulatory agenda planned the proposal for July 2026; it has not been published yet.
Why it matters: The 503A Bulks List decides which ingredients without a USP monograph or an approved drug, like most research peptides, US pharmacies may compound.
Overdue: the agenda's planned month was July 2026 (NPRM 07/00/2026). Placed in Q4 2026; agenda dates often slip.
-
Q4 2026
Trial results
Retatrutide vs semaglutide in type 2 diabetes (TRANSCEND-T2D-2)
Lilly's phase 3 TRANSCEND-T2D-2 compares weekly retatrutide with weekly semaglutide in adults with type 2 diabetes on metformin. Its registry record shows data collection for the main goal finished Aug 27, 2026; Lilly hasn't announced when results come.
Why it matters: A head-to-head of retatrutide against semaglutide (Ozempic) in type 2 diabetes.
Registry only: primary completion 2026-08-27 (actual), study completion 2027-02 (est.). Placed in Q4 2026 as results are pending; not a company date.
Source: ClinicalTrials.gov NCT06260722 (sponsor Eli Lilly and Company)
-
Q4 2026
Trial results
Survodutide's heart-safety trial (SYNCHRONIZE-CVOT) results
Boehringer Ingelheim expects to present results from SYNCHRONIZE-CVOT, survodutide's cardiovascular outcomes trial, 'later this year', per Zealand Pharma's Oct 1, 2026 announcement. No exact date is given.
Why it matters: It tests survodutide's heart safety in adults with heart disease, kidney disease or heart risk factors.
'Later this year' placed in Q4 2026.
Source: Zealand Pharma company announcement No. 52/2026 (Oct 1, 2026)
January 2027
-
Regulation
NICE guidance on orforglipron (Foundayo) for weight management in England
NICE is appraising orforglipron for managing obesity, or overweight with at least one weight-related condition. Its provisional schedule has a committee meeting on 10 November 2026 and expected publication on 27 January 2027.
Why it matters: NICE's guidance decides whether the NHS in England funds the Foundayo pill for weight management.
Provisional NICE schedule; committee meeting 2 is on 10 November 2026.
Source: NICE, Orforglipron for managing overweight and obesity [ID6516] (GID-TA11650)
-
Trial results
MariTide's phase 3 obesity trial (MARITIME-1)
Amgen's phase 3 MARITIME-1 tests maridebart cafraglutide (MariTide) for weight loss in adults with obesity without type 2 diabetes. The trial's registered finish date for its main goal is January 2027; Amgen hasn't announced when results come.
Why it matters: MariTide activates GLP-1 while blocking the GIP receptor, the opposite GIP approach to tirzepatide.
Registry only: primary completion 2027-01-21 (estimated).
February 2027
-
Results call
Novo Nordisk's full-year 2026 results
Novo Nordisk publishes its financial statement for 2026 and its Annual Report 2026 on Feb 3, 2027.
Why it matters: Full-year Wegovy, Ozempic and Wegovy pill sales, and Novo's outlook for 2027.
Source: Novo Nordisk H1 2026 financial report (Form 6-K), Financial Calendar
Q1 2027
The source gives the quarter, not the day.
-
Q1 2027
Trial results
CagriSema's REDEFINE 11 results
Novo Nordisk expects the readout of REDEFINE 11, a phase 3 CagriSema weight-management trial, in the first quarter of 2027, per its Sep 21, 2026 Capital Markets Day.
Why it matters: CagriSema's next phase 3 result, after its US decision expected in Q4 2026.
Source: Novo Nordisk Capital Markets Day 2026, obesity presentation (Sep 21, 2026)
-
Q1 2027
FDA decision
FDA decision on MASH (fatty liver) for the Wegovy pill
The FDA accepted Novo Nordisk's filing to add MASH data to the label of the Wegovy pill (oral semaglutide 25 mg), with a decision expected in Q1 2027. It rests on part 1 of the ESSENCE trial in MASH with F2–F3 liver fibrosis.
Why it matters: Would add MASH, fatty liver disease with liver scarring, to the Wegovy pill's US label.
Source: Novo Nordisk H1 2026 financial report (Form 6-K, Aug 4, 2026)
-
Q1 2027
FDA decision
Lilly files retatrutide with the FDA
Lilly plans to submit its Biologics License Application for retatrutide to the FDA in the first quarter of 2027, for obesity, obstructive sleep apnea and knee osteoarthritis pain. This is the filing, not an approval decision.
Why it matters: It starts the FDA's review of retatrutide, Lilly's weekly GIP, GLP-1 and glucagon triple agonist.
Kind 'fda' marks an FDA filing here, not a decision date.
Source: Eli Lilly Q2 2026 earnings release (Form 8-K, Aug 5, 2026)
May 2027
-
Conference
European Congress on Obesity 2027 (Munich)
The 34th European Congress on Obesity runs 18–21 May 2027 in Munich, Germany, as a joint congress of EASO and IFSO's European Chapter.
Why it matters: Europe's main obesity meeting; obesity drug trial results are often presented here.
Source: ECO 2027 official site (EASO)
June 2027
-
Conference
ENDO 2027, the Endocrine Society's annual meeting (Toronto)
The Endocrine Society holds ENDO 2027 on June 5–7, 2027, in Toronto, Ontario, Canada.
Why it matters: A major endocrinology meeting where obesity, diabetes and hormone research is presented.
One search listing showed June 5–8; the Society's future-meetings page says June 5–7.
-
Conference
EASL Congress 2027 (London)
The European Association for the Study of the Liver holds EASL Congress 2027 on 16–19 June 2027 in London, United Kingdom.
Why it matters: Europe's main liver meeting; MASH (fatty liver) results for incretin drugs often appear here.
-
Conference
ADA Scientific Sessions 2027 (Washington, DC)
The American Diabetes Association holds its 2027 Scientific Sessions on June 18–21, 2027, at the Walter E. Washington Convention Center in Washington, DC.
Why it matters: The main diabetes meeting of the year; Lilly held investor events at ADA in 2025 and 2026.
The page's banner image text reads 'June 10-21, 2027'; the page text says June 18–21.
Source: American Diabetes Association, Scientific Sessions page
Q2 2027
The source gives the quarter, not the day.
-
Q2 2027
Trial results
Cagrilintide alone for weight loss (RENEW 1)
Novo Nordisk's phase 3 RENEW 1 tests cagrilintide, the amylin half of CagriSema, on its own for weight loss in adults with overweight or obesity. The trial's registered finish date for its main goal is May 2027; Novo hasn't announced when results come.
Why it matters: A large trial of what amylin does on its own, without semaglutide.
Registry only: primary completion 2027-05-11 (estimated); placed in Q2 2027.
Source: ClinicalTrials.gov NCT07220642 (sponsor Novo Nordisk A/S)
September 2027
-
Conference
EASD 2027 annual meeting (Budapest)
The European Association for the Study of Diabetes holds its 2027 annual meeting from 20 to 24 September 2027 at HUNGEXPO in Budapest, Hungary.
Why it matters: Europe's main diabetes meeting; survodutide's SYNCHRONIZE-2 results were presented at EASD 2026.
After the July 2027 window; included because the brief asked for EASD 2027.
Source: EASD, Annual Meeting 2027 page
Already happened
-
Trial results
Petrelintide's ZUPREME-2 results (amylin, obesity with type 2 diabetes)
Zealand Pharma's phase 2 ZUPREME-2 trial of weekly petrelintide, an amylin analog, met its main goal: weight loss at 28 weeks versus placebo in adults with overweight or obesity and type 2 diabetes. Full results are due at an upcoming scientific conference.
Why it matters: Petrelintide is an amylin drug like cagrilintide; Zealand and Roche have started its phase 3 program (ZUPREME-3, -4 and -5).
Source: Zealand Pharma company announcement No. 54/2026 (Oct 7, 2026), Nasdaq Copenhagen
-
Trial results
Survodutide's SYNCHRONIZE-2 results (obesity with type 2 diabetes)
Boehringer Ingelheim's phase 3 SYNCHRONIZE-2 trial of survodutide gave up to 13.1% weight loss versus 3.1% on placebo in adults with obesity and type 2 diabetes, with better blood sugar control. Presented at EASD 2026 and published in NEJM.
Why it matters: Survodutide is a weekly GLP-1/glucagon dual agonist; its heart-safety trial, SYNCHRONIZE-CVOT, is the next readout, promised later this year.
Source: Zealand Pharma company announcement No. 52/2026 (Oct 1, 2026)
PepVault for iPhone
Track it in the app.
Log your doses, vials and injection sites, with every peptide’s studied range a tap away.
